ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

VRDN // Viridian Therapeutics Inc.

ANR <GO> NASDAQ RQD COCKPIT → CIK 0001590750 ↗
Health Care • Biotechnology: Pharmaceutical Preparations
$24.67 ▼ -0.13 (-0.52%)
MKT CAP: $2.81B • VOL: 1.71M
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8 SELL: 2
12M STREET TARGET RANGE IMPLIED: +14.0%
LOW
$21
MEDIAN
$28
MEAN
$28
HIGH
$34
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100 EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE VRDN TAPE
VRDN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>) CURRENT 90D STREET CONSENSUS
INSTITUTION / ANALYST ACTION RATING TARGET PRIOR PT CALL DATE PX AT CALL RET SINCE CALL 1Y ACCURACY BS GRADE
Morgan Stanley Institutional
Equity Desk
REITERATE OUTPERFORM $29.85 $28.37 2025-02-14 $22.45 +9.9% 78% A
Goldman Sachs Global Research
Sector Coverage
TARGET REV STRONG BUY $31.08 $29.11 2025-02-06 $23.19 +6.4% 74% A
J.P. Morgan Securities
US Large Cap
REITERATE BUY $28.12 $27.14 2025-01-29 $23.68 +4.2% 67% B
Bernstein Autonomous
Forensic Coverage
INITIATE HOLD $25.16 — 2025-01-17 $24.18 +2.0% 61% B
Barclays Capital
Americas Research
DOWNGRADE UNDERPERFORM $21.71 $23.44 2025-01-09 $21.96 -11.2% 42% D
UBS Investment Bank
Institutional Desk
UPGRADE BUY $29.36 $25.66 2024-12-18 $21.46 +14.9% 72% A
Citigroup Global Markets
Sector Lead
TARGET REV HOLD $23.93 $24.92 2024-12-04 $22.94 -4.3% 48% C